Literature DB >> 14743504

Expression of BRCA1 protein in benign, borderline, and malignant epithelial ovarian neoplasms and its relationship to methylation and allelic loss of the BRCA1 gene.

Cuiju Wang1, Akiko Horiuchi, Tsutomu Imai, Satoshi Ohira, Kazuko Itoh, Toshio Nikaido, Yoshihiko Katsuyama, Ikuo Konishi.   

Abstract

BRCA1 is a putative tumour suppressor gene responsible for a hereditary ovarian cancer syndrome. To clarify the possible involvement of BRCA1 in the development of sporadic ovarian neoplasms, this study analysed the immunohistochemical expression of BRCA1 protein in normal ovarian surface epithelium and 119 epithelial ovarian tumours (19 benign, 24 borderline, and 76 malignant tumours). Loss of heterozygosity (LOH) of BRCA1 was examined using three microsatellite markers to analyse the relationship between BRCA1 expression and alterations of the BRCA1 gene. Methylation of the BRCA1 promoter was also analysed by methylation-specific PCR. In ovarian carcinomas showing heterogeneous expression of BRCA1 protein in the same tumour, LOH and methylation status were analysed using microdissection techniques. Finally, the relationship of BRCA1 expression or its genetic alteration to clinicopathological parameters and patient survival was analysed. Ovarian surface epithelial cells expressed BRCA1 protein. Decreased expression of BRCA1 was found in 16% of benign tumours, 38% of borderline tumours, and 72% of carcinomas. LOH of BRCA1 was demonstrated in no benign tumours, 15% of borderline tumours, and 66% of carcinomas. Methylation of BRCA1 was not detected in benign or borderline tumours, but was present in 31% of carcinomas. Reduced expression of BRCA1 correlated with the presence of gene methylation. The frequency of BRCA1 methylation and LOH was higher in serous carcinomas than in other types. In one of the three serous carcinomas that showed heterogeneous expression of BRCA1, BRCA1-positive borderline-like tumour cells were LOH-positive and methylation-negative, whereas adjacent BRCA1-negative carcinoma cells were LOH-positive and methylation-positive. The prognosis of carcinoma patients did not correlate with BRCA1 expression or genetic status. These findings suggest that reduced expression of BRCA1 protein along with genetic and epigenetic changes of the BRCA1 gene play an important role in the development of sporadic ovarian carcinomas, particularly those of serous histology. Copyright 2004 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14743504     DOI: 10.1002/path.1507

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  33 in total

Review 1.  DNA methylation: its role in cancer development and therapy.

Authors:  Carla Kurkjian; Shivaani Kummar; Anthony J Murgo
Journal:  Curr Probl Cancer       Date:  2008 Sep-Oct       Impact factor: 3.187

Review 2.  Ovarian cancer.

Authors:  Kathleen R Cho; Ie-Ming Shih
Journal:  Annu Rev Pathol       Date:  2009       Impact factor: 23.472

3.  The Cables gene on chromosome 18q is silenced by promoter hypermethylation and allelic loss in human colorectal cancer.

Authors:  Do Youn Park; Hideo Sakamoto; Sandra D Kirley; Shuji Ogino; Takako Kawasaki; Eunjeong Kwon; Mari Mino-Kenudson; Gregory Y Lauwers; Daniel C Chung; Bo R Rueda; Lawrence R Zukerberg
Journal:  Am J Pathol       Date:  2007-11       Impact factor: 4.307

4.  Clinically applicable models to characterize BRCA1 and BRCA2 variants of uncertain significance.

Authors:  Andrew D Spearman; Kevin Sweet; Xiao-Ping Zhou; Jane McLennan; Fergus J Couch; Amanda Ewart Toland
Journal:  J Clin Oncol       Date:  2008-09-29       Impact factor: 44.544

5.  BRCA1 as a Therapeutic Target in Sporadic Epithelial Ovarian Cancer.

Authors:  Katherine V Clark-Knowles; Anna M O'Brien; Johanne I Weberpals
Journal:  J Oncol       Date:  2010-02-22       Impact factor: 4.375

6.  Germline variation controls the architecture of somatic alterations in tumors.

Authors:  Amy M Dworkin; Katie Ridd; Dianne Bautista; Dawn C Allain; O Hans Iwenofu; Ritu Roy; Boris C Bastian; Amanda Ewart Toland
Journal:  PLoS Genet       Date:  2010-09-23       Impact factor: 5.917

7.  Neurofibromin 1 (NF1) defects are common in human ovarian serous carcinomas and co-occur with TP53 mutations.

Authors:  Navneet Sangha; Rong Wu; Rork Kuick; Scott Powers; David Mu; Diane Fiander; Kit Yuen; Hidetaka Katabuchi; Hironori Tashiro; Eric R Fearon; Kathleen R Cho
Journal:  Neoplasia       Date:  2008-12       Impact factor: 5.715

Review 8.  MYC in breast tumor progression.

Authors:  Yinghua Chen; Olufunmilayo I Olopade
Journal:  Expert Rev Anticancer Ther       Date:  2008-10       Impact factor: 4.512

9.  Methylation and protein expression of DNA repair genes: association with chemotherapy exposure and survival in sporadic ovarian and peritoneal carcinomas.

Authors:  Elizabeth M Swisher; Rachel M Gonzalez; Toshiyasu Taniguchi; Rochelle L Garcia; Tom Walsh; Barbara A Goff; Piri Welcsh
Journal:  Mol Cancer       Date:  2009-07-14       Impact factor: 27.401

10.  BRCA1 Expression is an Important Biomarker for Chemosensitivity: Suppression of BRCA1 Increases the Apoptosis via Up-regulation of p53 and p21 During Cisplatin Treatment in Ovarian Cancer Cells.

Authors:  Akiko Horiuchi; Cuiju Wang; Norihiko Kikuchi; Ryosuke Osada; Toshio Nikaido; Ikuo Konishi
Journal:  Biomark Insights       Date:  2007-03-02
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.